



501-3292 Production Way, Burnaby, B.C., V5A 4R4

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety.

Vancouver, British Columbia, June 18, 2018 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of $\Delta 9$ -tetrahydrocannabinol ("THC"), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards. In addition, scientists have made significant progress towards using lower flow rates that will become important for user groups with poor lung function. Furthermore, engineers have been testing a new breath capture method that can hold THC breath samples in a stable manner for several days.

$\Delta 9$ -tetrahydrocannabinol ("THC") the main psychoactive component of marijuana is metabolized into and 11-nor-9-carboxy-tetrahydrocannabinol at different rates based on route of entry into the body. Smoked THC is converted predominantly to 11-nor-9-carboxy-tetrahydrocannabinol which is then glucuronidated to a water-soluble form that can be detected in body fluids. Ingested THC is metabolized via the hepatic portal circulation to 11-hydroxy-delta-9-tetrahydrocannabinol prior to oxidation to 11-nor-9-carboxy-tetrahydrocannabinol. The Cannabix FAIMS device coupled to real time switchable mass spectrometry is actively being tuned to detect these key molecules and their complex pathways in the body to enable the identification of recency of use.

The recent passing of legislation Bill C-45 by the Senate of Canada and legislative developments in the State of Vermont, have increased the number of inquiries for the Cannabix breathalyzer device and the Company has received interest in piloting from both U.S. and Canadian law enforcement groups as well as other organizations that drug test their employees. The Senate Judiciary Committee in the state of Vermont recently rejected a bill to use saliva testing for THC enforcement, amid concerns of scientific validity, accuracy, and infringement on civil liberties.

Rav Mlait, CEO, stated, "With the passing of Bill C-45 in Canada the growing problem of drugged driving will increasingly become an issue of paramount concern for federal, provincial and civic governmental officials and the public at large who are concerned about maintaining public safety on our roads, institutions and in our workplaces. A recent study by the Governors Highway Safety Association found that drugs are being detected more often in drivers responsible for fatal crashes. The problem of drugged driving is compounded by lack of nationally accepted method for testing drugged driver impairment. Cannabix Technologies has been at the forefront of research and development in this arena and understands the complexities related to breath testing for marijuana. As the issue of drugged driving becomes increasingly acute, Cannabix is committed to using its

technology, R&D and scientific experience to provide effective tools to aid law enforcement and help governments and the public transition to marijuana legalization in various jurisdictions.”

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.